More women are writing checks at European VC firms, but female-led startups are raising less capital even as funding for their male-led counterparts grows.
According to PitchBook’s 2025 European All In Report, female representation at the fund level has improved, with 13% of decision-makers at European VC firms with AUM of less than €50 million (about $58 million) being women. This is compared to just 8.3% in 2024.
For larger firms, with more than €50 million in AUM, the increase has been slower, 16.5% in 2025 versus 15% the previous year, but it is a positive signal that Europe’s investors are becoming more diverse.
While the lack of female investors is often cited as a key factor in the underfunding of women-founded startups, the modest improvement in investment board representation has not translated into more investment for female-led businesses.
Last year, female founders’ share of overall dealmaking has continued to slip to just 16.5% of deal value, down from 20.4% in 2024 and less than a quarter of deal count.
In total, women raised €9.5 billion in funding, more than 15% less than in 2024 and the fourth consecutive annual decline. By contrast, all-male-founded companies saw a growth in deal value, although round count has similarly declined.
Even in markets where capital is flowing more freely, female founders are receiving just a sliver of funding. Investment in AI, for example, totaled €23.5 billion, of which only €3 billion went to women-founded startups. Very few of the startups raising mega-rounds have female founders—exceptions include AI video startup Synthesia and quantum AI software company Multiverse, both of which raised rounds over €100 million last year.
There are markets with better representation, particularly in life sciences and femtech. VC deal value for female-led femtech startups broke its two-year streak in 2025, growing almost 25% from 2024.
Female founders’ strength in life sciences and biotech led to some of 2025’s largest exits. Cancer therapy developer Araris Biotech was bought by Taiho Pharmaceutical in March for more than €1 billion, while Atai Life Sciences acquired mental health-focused Beckley Psytech for €345.9 million in November.
Latest Research
European VC Valuations Report
Recent News
Apollo views daily pricing as key to expanding alternatives access. Industry peers are skeptical.
Sellers to stakeholders: CLOs step up in European restructurings
Learn about our editorial standards.